{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:35:25Z","timestamp":1766086525708},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.vaccine.2008.11.034","type":"journal-article","created":{"date-parts":[[2008,12,5]],"date-time":"2008-12-05T16:21:01Z","timestamp":1228494061000},"page":"624-628","source":"Crossref","is-referenced-by-count":31,"title":["MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials\u2014Scientific, regulatory and public health perspectives"],"prefix":"10.1016","volume":"27","author":[{"given":"Vasee S.","family":"Moorthy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarifah","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2008.11.034_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1475-2875-7-180","article-title":"A community effectiveness trial of strategies promoting intermittent preventive treatment with sulphadoxine-pyrimethamine in pregnant women in rural Burkina Faso","volume":"7","author":"Gies","year":"2008","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2008.11.034_bib2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1472-6963-8-165","article-title":"From strategy development to routine implementation: the cost of Intermittent Preventive Treatment in Infants for malaria control","volume":"8","author":"Manzi","year":"2008","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.vaccine.2008.11.034_bib3","doi-asserted-by":"crossref","first-page":"e1471","DOI":"10.1371\/journal.pone.0001471","article-title":"A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children","volume":"3","author":"Sokhna","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2008.11.034_bib4","unstructured":"WHO Global Malaria Programme. World Malaria Report; 2008. www.who.int\/malaria."},{"issue":"9502","key":"10.1016\/j.vaccine.2008.11.034_bib5","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(05)67669-6","article-title":"Duration of protection with RTS,S\/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial","volume":"366","author":"Alonso","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2008.11.034_bib6","unstructured":"Malaria Vaccine Technology Roadmap Final Report; 2006. www.malariavaccineroadmap.net."},{"issue":"4","key":"10.1016\/j.vaccine.2008.11.034_bib7","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1086\/318534","article-title":"Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria","volume":"183","author":"Kester","year":"2001","journal-title":"J Infect Dis"},{"issue":"29","key":"10.1016\/j.vaccine.2008.11.034_bib8","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1016\/j.vaccine.2007.05.005","article-title":"A phase I\/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S\/AS02A in malaria-naive adults","volume":"25","author":"Kester","year":"2007","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2008.11.034_bib9","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2008.02.048","article-title":"Phase 2a trial of 0,1 and 3 month and 0, 7 and 28 day immunization schedules of malaria vaccine RTS,S\/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research","volume":"26","author":"Kester","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2008.11.034_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/ije\/13.1.87","article-title":"Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies","volume":"13","author":"Smith","year":"1984","journal-title":"Int J Epidemiol"},{"issue":"6","key":"10.1016\/j.vaccine.2008.11.034_bib11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1086\/339342","article-title":"A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea","volume":"185","author":"Genton","year":"2002","journal-title":"J Infect Dis"},{"issue":"9297","key":"10.1016\/j.vaccine.2008.11.034_bib12","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(01)06957-4","article-title":"Efficacy of RTS,S\/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomised trial","volume":"358","author":"Bojang","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2008.11.034_bib13","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1371\/journal.pmed.0010033","article-title":"A randomised, double-blind, controlled vaccine efficacy trial of DNA\/MVA ME-TRAP against malaria infection in Gambian adults","volume":"1","author":"Moorthy","year":"2004","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.vaccine.2008.11.034_bib14","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1371\/journal.pctr.0010029","article-title":"A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya","volume":"1","author":"Bejon","year":"2006","journal-title":"PLoS Clin Trials"},{"issue":"9443","key":"10.1016\/j.vaccine.2008.11.034_bib15","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(04)17223-1","article-title":"Efficacy of the RTS,S\/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial","volume":"364","author":"Alonso","year":"2004","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.vaccine.2008.11.034_bib16","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1016\/j.vaccine.2007.01.085","article-title":"Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation","volume":"25","author":"Moorthy","year":"2007","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08015867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08015867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,23]],"date-time":"2018-12-23T22:28:41Z","timestamp":1545604121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X08015867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0264410X08015867"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2008.11.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}